Cargando…
Inhibitor Development against p7 Channel in Hepatitis C Virus
Hepatitis C Virus (HCV) is the key cause of chronic and severe liver diseases. The recent direct-acting antiviral agents have shown the clinical success on HCV-related diseases, but the rapid HCV mutations of the virus highlight the sustaining necessity to develop new drugs. p7, the viroporin protei...
Autores principales: | Wei, Shukun, Hu, Xiaoyou, Du, Lingyu, Zhao, Linlin, Xue, Hongjuan, Liu, Chaolun, Chou, James J., Zhong, Jin, Tong, Yimin, Wang, Shuqing, OuYang, Bo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7961618/ https://www.ncbi.nlm.nih.gov/pubmed/33802584 http://dx.doi.org/10.3390/molecules26051350 |
Ejemplares similares
-
Identification of a novel class of cyclic penta-peptides against hepatitis C virus as p7 channel blockers
por: Wei, Shukun, et al.
Publicado: (2022) -
Structural basis of interaction between the hepatitis C virus p7 channel and its blocker hexamethylene amiloride
por: Zhao, Linlin, et al.
Publicado: (2016) -
NMR Detection and Structural Modeling of the Ethylene Receptor LeETR2 from Tomato
por: Wei, Shukun, et al.
Publicado: (2022) -
Unusual architecture of the p7 channel from hepatitis C virus
por: OuYang, Bo, et al.
Publicado: (2013) -
Regulation of PD-L1 through direct binding of cholesterol to CRAC motifs
por: Wang, Qian, et al.
Publicado: (2022)